Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion - Public policy

4743 - Determinants of the Cancer Drug Funding Process in Canada

Date

29 Sep 2019

Session

Poster Discussion - Public policy

Presenters

Joanna Gotfrit

Citation

Annals of Oncology (2019) 30 (suppl_5): v671-v682. 10.1093/annonc/mdz263

Authors

J. Gotfrit1, J.J.W. Shin2, R. Mallick3, P. Wheatley-Price1

Author affiliations

  • 1 Medical Oncology, The Ottawa Hospital Regional Cancer Centre, K1H 8L6 - Ottawa/CA
  • 2 Undergraduate Medical Education, University of Ottawa, K1H8L6 - Ottawa/CA
  • 3 Ottawa Hospital Research Institute, University of Ottawa, K1H8L6 - Ottawa/CA

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4743

Background

Canada has a publicly-funded healthcare system with a complex drug funding process. After Health Canada approval to market a drug, the pan-Canadian Oncology Drug Review (pCODR) makes a non-binding funding recommendation to the Canadian provinces (except Quebec), which each then decide whether the drug will be publicly funded. We identified the determinants of funding in this process.

Methods

We analyzed drugs for advanced lung (n = 15), breast (n = 8), colorectal (CRC) (n = 7), melanoma (n = 10), and neuroendocrine (NET) (n = 3) cancer undergoing the funding decision process from 2011-2019. Determinants of funding assessed in the model included list price, cancer type, drug class, and pCODR recommendation. The primary outcome was the correlation between list price and time-to-funding (TTF: Health Canada approval to first provincial funding). Secondary outcomes included an exploratory analysis of predictors of drug funding.

Results

We analyzed 43 drugs: targeted agents 72%, immunotherapy 20%, chemotherapy 7%. 72% were funded in at least 1 province. Median TTF was 379 days (IQR 203-601). Median list price (28-day course) was $8213 (IQR 5391-9445). Higher list price was not correlated with TTF (correlation coefficient -0.20, p = 0.28). There was no association between list price and pCODR recommendation, or the decision to fund in at least 1 province. A positive pCODR recommendation correlated with the provinces’ funding decisions (p < 0.001), where 89% of drugs with a positive recommendation were funded and 100% of drugs with a negative recommendation were not funded. Tumour type was predictive of TTF (p < 0.001): CRC drugs slowest at a median of 2541 days (IQR 702-4379), and NET drugs quickest at a median of 0 days (IQR 0-502). Cancer type predicted decision to fund in at least 1 province (p = 0.005), with funding for 100% of NET drugs at the high end and 29% of CRC drugs at the low end. Drug class was predictive of TTF (p = 0.01): 465 days (IQR 245-702) for targeted agents, 443 days (IQR 298-587) for chemotherapy, and 339 days (IQR 164-446) for immunotherapy.

Conclusions

Determinants of drug funding include cancer type, drug class, and pCODR recommendation, but not list price. Factors other than cost are more heavily weighted in the funding decisions of cancer drugs in Canadian provinces.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Paul Wheatley-Price and Joanna Gotfrit.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.